nach oben

Erschienen in:

27.02.2021 | Guidelines

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

verfasst von: Harshad Devarbhavi, Guruprasad Aithal, Sombat Treeprasertsuk, Hajime Takikawa, Yimin Mao, Saggere M. Shasthry, Saeed Hamid, Soek Siam Tan, Cyriac Abby Philips, Jacob George, Wasim Jafri, Shiv K. Sarin, on behalf of the Asia Pacific Association of Study of Liver

Erschienen in: Hepatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Idiosyncratic drug-induced liver injury mimics acute and chronic liver disease. It is under recognized and underrecognised because of the lack of pathognomonic diagnostic serological markers. Its consequences may vary from being asymptomatic to self-limiting illness to severe liver injury leading to acute liver failure. Its incidence is likely to be more common in Asia than other parts of the world, mainly because of hepatotoxicity resulting from the treatment of tuberculosis disease and the ubiquitous use of traditional and complimentary medicines in Asian countries. This APASL consensus guidelines on DILI is a concise account of the various aspects including current evidence-based information on DILI with special emphasis on DILI due to antituberculosis agents and traditional and complementary medicine use in Asia.

World Health Organization. Global tuberculosis report 2019:1–283

Saukkonen JJ, Cohn DL, Jasmer RM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935–952.PubMed

World HealthOrganization. Traditional Medicine Strategy 2014–23. 2013.

Shen T, Liu Y, Shang J, et al. Incidence and etiology of drug-induced liver injury in Mainland China. Gastroenterology 2019;156:2230–2241.PubMed

Björnsson HK, Björnsson ES, Avula B, et al. Ashwagandha-induced liver injury: a case series from Iceland and the US drug-induced liver injury network. Liver Int 2020;40:825–829.PubMedPubMedCentral

Sgro C, Clinard F, Ouazir K, et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 2002;36:451–455.PubMed

Bjornsson ES, Bergmann OM, Bjornsson HK, et al. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013;144:1419–1425.PubMed

Suk KT, Kim DJ, Kim CH, et al. A prospective nationwide study of drug-induced liver injury in Korea. Am J Gastroenterol 2012;107:1380–1387.PubMed

Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott; 1999.

10.

Aithal GP, Watkins PB, Andrade RJ, et al. Case definition and phenotype standardization in drug-induced liver injury. Clin Pharmacol Ther 2011;89:806–815.PubMed

11.

Group GW. Grading quality of evidence and strength of recommendations. BMJ 2004;328:1490.

12.

Moore TJ, Cohen MR, Furberg CD. Serious adverse drug events reported to the Food and Drug Administration, 1998–2005. Arch Intern Med 2007;167:1752–1759.PubMed

13.

Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993;46:1323–1330.PubMed

14.

Lucena MI, Andrade RJ, Kaplowitz N, et al. Phenotypic characterization of idiosyncratic drug-induced liver injury: the influence of age and sex. Hepatology 2009;49:2001–2009.PubMed

15.

Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology 2015;148:1340–1352.PubMed

16.

Tostmann A, Boeree MJ, Aarnoutse RE, et al. Antituberculosis drug-induced hepatotoxicity: concise up-to-date review. J Gastroenterol Hepatol 2008;23:192–202.PubMed

17.

Fountain FF, Tolley E, Chrisman CR, et al. Isoniazid hepatotoxicity associated with treatment of latent tuberculosis infection: a 7-year evaluation from a public health tuberculosis clinic. Chest 2005;128:116–123.PubMed

18.

Bryant AE, Dreifuss FE. Valproic acid hepatic fatalities. III. US experience since 1986. Neurology 1996;46:465–469.PubMed

19.

Cai Y, Yi J, Zhou C, et al. Pharmacogenetic study of drug-metabolising enzyme polymorphisms on the risk of anti-tuberculosis drug-induced liver injury: a meta-analysis. PLoS ONE 2012;7:e47769. PubMedPubMedCentral

20.

Nicoletti P, Devarbhavi H, Goel A, et al. Genome-wide association study (GWAS) to identify genetic risk factors that increase susceptibility to antituberculosis drug-induced liver injury (ATDILI). Hepatology 2017;66:Abstract-25.

21.

Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011;141:338–347.PubMed

22.

Cirulli ET, Nicoletti P, Abramson K, et al. A missense variant in PTPN22 is a risk factor for drug-induced liver injury. Gastroenterology 2019;156(1707–1716):e2.

23.

Zimmerman HJ. Effects of alcohol on other hepatotoxins. Alcohol Clin Exp Res 1986;10:3–15.PubMed

24.

Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408 women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932.PubMedPubMedCentral

25.

Saphner T, Triest-Robertson S, Li H, et al. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009;115:3189–195.PubMed

26.

Wong WM, Wu PC, Yuen MF, et al. Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection. Hepatology 2000;31:201–206.PubMed

27.

Chalasani N, Bjornsson E. Risk factors for idiosyncratic drug-induced liver injury. Gastroenterology 2010;138:2246–2259.PubMed

28.

Russo MW, Watkins PB. Are patients with elevated liver tests at increased risk of drug-induced liver injury? Gastroenterology 2004;126:1477–1480.PubMed

29.

Sarma GR, Immanuel C, Kailasam S, et al. Rifampin-lnduced release of hydrazine from isoniazid: a possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am Rev Respir Dis 1986;133:1072–1075.PubMed

30.

Balzarini J, Lee CK, Herdewijn P, et al. Mechanism of the potentiating effect of ribavirin on the activity of 2’,3’-dideoxyinosine against human immunodeficiency virus. J Biol Chem 1991;266:21509–21514.PubMed

31.

Mira JA, Macías J, Girón-González JA, et al. Incidence of and risk factors for severe hepatotoxicity of nelfinavir-containing regimens among HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2006;58:140–146.PubMed

32.

Navarro VJ, Barnhart H, Bonkovsky HL, et al. Liver injury from herbals and dietary supplements in the US drug-induced liver injury network. Hepatology 2014;60:1399–1408.PubMed

33.

Bailey RL, Gahche JJ, Lentino CV, et al. Dietary supplement use in the United States, 2003–2006. J Nutr 2011;141:261–266.PubMed

34.

Andrade RJ, Lucena MI, Fernandez MC, et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005;129:512–521. PubMed

35.

Medina-Caliz I, Robles-Diaz M, Garcia-Munoz B, et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. J Hepatol 2016;65:532–542.PubMedPubMedCentral

36.

Lee T, Lee YS, Yoon SY, et al. Characteristics of liver injury in drug-induced systemic hypersensitivity reactions. J Am Acad Dermatol 2013;69:407–415.PubMed

37.

Devarbhavi H, Karanth D, Prasanna KS, et al. Drug-Induced liver injury with hypersensitivity features has a better outcome: a single-center experience of 39 children and adolescents. Hepatology 2011;54:1344–1350.PubMed

38.

Devarbhavi H, Raj S, Aradya VH, et al. Drug-induced liver injury associated with stevens-Johnson syndrome/toxic epidermal necrolysis: patient characteristics, causes, and outcome in 36 cases. Hepatology 2016;63:993–999.PubMed

39.

Knowles SR, Dewhurst N, Shear NH. Anticonvulsant hypersensitivity syndrome: an update. Expert Opin Drug Saf 2012;11:767–778.PubMed

40.

Benichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990;11:272–276.PubMed

41.

Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med 2006;354:731–739.PubMed

42.

Licata A, Maida M, Cabibi D, et al. Clinical features and outcomes of patients with drug-induced autoimmune hepatitis: a retrospective cohort study. Dig Liver Dis 2014;46:1116–120.PubMed

43.

Bjornsson E, Talwalkar J, Treeprasertsuk S, et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010;51:2040–2048.PubMed

44.

Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999;44:731–735.PubMedPubMedCentral

45.

de Boer YS, Kosinski AS, Urban TJ, et al. Features of autoimmune hepatitis in patients with drug-induced liver injury. Clin Gastroenterol Hepatol 2017;15(103–112):e2.

46.

Lucena MI, Kaplowitz N, Hallal H, et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J Hepatol 2011;55:820–827.PubMed

47.

Rodrigues S, Lopes S, Magro F, et al. Autoimmune hepatitis and anti-tumor necrosis factor alpha therapy: a single center report of 8 cases. World J Gastroenterol 2015;21:7584–7588.PubMedPubMedCentral

48.

Perdices EV, Medina-Caliz I, Hernando S, et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. Rev Esp Enferm Dig 2014;106:246–254.PubMed

49.

Larrey D. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis 2002;22:145–155.PubMed

50.

Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.PubMed

51.

Dawwas MF, Aithal GP. End-stage methotrexate-related liver disease is rare and associated with features of the metabolic syndrome. Aliment Pharmacol Ther 2014;40:938–948.PubMed

52.

Raja K, Thung SN, Fiel MI, et al. Drug-induced steatohepatitis leading to cirrhosis: long-term toxicity of amiodarone use. Semin Liver Dis 2009;29:423–438.PubMed

53.

Miyake K, Hayakawa K, Nishino M, et al. Effects of oral 5-fluorouracil drugs on hepatic fat content in patients with colon cancer. Acad Radiol 2005;12:722–727.PubMed

54.

Andrade RJ, Lucena MI, Kaplowitz N, et al. Outcome of acute idiosyncratic drug-induced liver injury: long-term follow-up in a hepatotoxicity registry. Hepatology 2006;44:1581–1588.PubMed

55.

Robles-Diaz M, Garcia-Cortes M, Medina-Caliz I, et al. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver Int 2015;35:2474–2482.PubMed

56.

Temple R. Hy’s law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006;15:241–243.PubMed

57.

Chalasani N, Fontana RJ, Bonkovsky HL, et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008;135:1924–1934 ((1934 e1–4)).PubMed

58.

Horsley-Silva JL, Dow EN, Menias CO, et al. Docetaxel induced sclerosing cholangitis. Dig Dis Sci 2015;60:3814–3816.PubMed

59.

Ludwig J, Kim CH, Wiesner RH, et al. Floxuridine-induced sclerosing cholangitis: an ischemic cholangiopathy? Hepatology 1989;9:215–218.PubMed

60.

Ramachandran R, Kakar S. Histological patterns in drug-induced liver disease. J Clin Pathol 2009;62:481–492.PubMed

61.

Kleiner DE, Chalasani NP, Lee WM, et al. Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014;59:661–670.PubMed

62.

Arimone Y, Bégaud B, Miremont-Salamé G, et al. Agreement of expert judgment in causality assessment of adverse drug reactions. Eur J Clin Pharmacol 2005;61:169–173.PubMed

63.

Aithal GP, Rawlins MD, Day CP. Accuracy of hepatic adverse drug reaction reporting in one English health region. BMJ 1999;319:1541.PubMedPubMedCentral

64.

Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993;46:1331–1336.PubMed

65.

Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. Am J Gastroenterol 2014;109:950–966.PubMed

66.

Andrade RJ, Aithal GP, Björnsson ES, et al. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol. 2019;70:1222–1261.

67.

Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997;26:664–669.PubMed

68.

Lucena MI, Camargo R, Andrade RJ, et al. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 2001;33:123–130.PubMed

69.

Tillmann HL, Suzuki A, Barnhart HX, et al. Tools for causality assessment in drug-induced liver disease. Curr Opin Gastroenterol. 2019;35:183–190.PubMedPubMedCentral

70.

Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117–2126.PubMed

71.

Takikawa H, Onji M. A proposal of the diagnostic scale of drug-induced liver injury. Hepatol Res. 2005;32:250–251.PubMed

72.

Takikawa H, Onji M, Takamori Y, et al. Proposal of diagnostic criteria for drug-induced liver injury revised by the DDW-J 2004 workshop. Kanzo. 2005;46:85–90.

73.

Kanayama A, Arima Y, Yamagishi T, et al. Epidemiology of domestically acquired hepatitis E virus infection in Japan: assessment of the nationally reported surveillance data, 2007–2013. J Med Microbiol 2015;64:752–758.PubMed

74.

Hanatani T, Sai K, Tohkin M, et al. A detection algorithm for drug-induced liver injury in medical information databases using the Japanese diagnostic scale and its comparison with the council for international organizations of medical sciences/the roussel uclaf causality assessment method scale. Pharmacoepidemiol Drug Saf 2014;23:984–988.PubMed

75.

Whritenour J, Ko M, Zong Q, et al. Development of a modified lymphocyte transformation test for diagnosing drug-induced liver injury associated with an adaptive immune response. J Immunotoxicol 2017;14:31–38.PubMedPubMedCentral

76.

Fontana RJ, Hayashi PH, Gu J, et al. Idiosyncratic drug-induced liver injury is associated with substantial morbidity and mortality within 6 months from onset. Gastroenterology 2014;147(96–108):e4.

77.

Hunt CM. Mitochondrial and immunoallergic injury increase risk of positive drug rechallenge after drug-induced liver injury: a systematic review. Hepatology 2010;52:2216–2222.PubMed

78.

Hunt CM, Papay JI, Stanulovic V, et al. Drug rechallenge following drug-induced liver injury. Hepatology 2017;66:646–654.PubMed

79.

Papay JI, Clines D, Rafi R, et al. Drug-induced liver injury following positive drug rechallenge. Regul Toxicol Pharmacol 2009;54:84–90.PubMed

80.

Sharma SK, Singla R, Sarda P, et al. Safety of 3 different reintroduction regimens of antituberculosis drugs after development of antituberculosis treatment-induced hepatotoxicity. Clin Infect Dis 2010;50:833–839.PubMed

81.

Ataç G, Sevim T, Törün T, et al. The management of anti-tuberculosis drug-induced hepatotoxicity. Int J Tuberc Lung Dis 2001;5:65–69.PubMed

82.

https://www.fundingawards.nihr.ac.uk/award/NIHR129515

83.

Powles T, Bracarda S, Chen M, et al. Characterisation of liver chemistry abnormalities associated with pazopanib monotherapy: a systematic review and meta-analysis of clinical trials in advanced cancer patients. Eur J Cancer 2015;51:1293–1302.PubMedPubMedCentral

84.

Daly AK, Donaldson PT, Bhatnagar P, et al. HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin. Nat Genet 2009;41:816–819.PubMed

85.

Aithal GP. Of potions, poisons, polygonum and pre-emptive polymorphism. Hepatology 2019;70:8–10.PubMed

86.

Kaliyaperumal K, Grove JI, Delahay RM, et al. Pharmacogenomics of drug-induced liver injury (DILI): molecular biology to clinical applications. J Hepatol 2018;69:948–957.PubMed

87.

Aithal GP. Pharmacogenetic testing in idiosyncratic drug-induced liver injury: current role in clinical practice. Liver Int 2015;35:1801–1808.PubMed

88.

Lohse AW, Chazouilleres O, Dalekos G, et al. EASL clinical practice guidelines: autoimmune hepatitis. J Hepatol 2015;63:971–1004.

89.

Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929–938.PubMed

90.

https://c-path.org/critical-path-institute-receives-regulatory-support-for-liver-injury-biomarker/

91.

Church RJ, Kullak-Ublick GA, Aubrecht J, et al. Candidate biomarkers for the diagnosis and prognosis of drug-induced liver injury: an international collaborative effort. Hepatology 2019;69:760–773.PubMed

92.

Bjornsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005;42:481–489.PubMed

93.

Robles-Diaz M, Lucena MI, Kaplowitz N, et al. Use of Hy’s law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. Gastroenterology 2014;147:109–118.PubMed

94.

Olsson R, Wiholm B-E, Sand C, et al. Liver damage from flucloxacillin, cloxacillin and dicloxacillin. J Hepatol 1992;15:154–161.PubMed

95.

Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009;50:511–517.PubMed

96.

Hayashi PH, Fontana RJ. Clinical features, diagnosis, and natural history of drug-induced liver injury. In: Seminars in liver disease. Thieme Medical Publishers 2014.

97.

Devarbhavi H, Dierkhising R, Kremers WK, et al. Single-center experience with drug-induced liver injury from India: causes, outcome, prognosis, and predictors of mortality. Am J Gastroenterol 2010;105:2396–2404.PubMed

98.

Prakash A, Jarvis B. Leflunomide: a review of its use in active rheumatoid arthritis. Drugs 1999;58:1137–1164.PubMed

99.

Bohan TP, Helton E, McDonald I, et al. Effect of l-carnitine treatment for valproate-induced hepatotoxicity. Neurology 2001;56:1405–1409.PubMed

100.

Lheureux PE, Hantson P. Carnitine in the treatment of valproic acid-induced toxicity. Clin Toxicol (Phila) 2009;47:101–111.

101.

Chan Y-C, Tse M, Lau FL. Two cases of valproic acid poisoning treated with l-carnitine. Hum Exp Toxicol 2007;26:967–969.PubMed

102.

Glatstein M, Rino PB, de Pinho S, et al. Levocarnitine for the treatment of valproic acid-induced hyperammonemic encephalopathy in children: the experience of a large, Tertiary Care Pediatric Hospital and a Poison Center. Am J Ther 2019;26:e344–e349.PubMed

103.

Health NIo. Livertox: clinical and research information on drug-induced liver injury. Nih. gov https://www.livertox/nih.gov 2017.

104.

Lee WM, Hynan LS, Rossaro L, et al. Intravenous N-acetylcysteine improves transplant-free survival in early stage non-acetaminophen acute liver failure. Gastroenterology 2009;137:856–864.PubMed

105.

Borlak J, van Bömmel F, Berg T. N-Acetylcysteine and prednisolone treatment improved serum biochemistries in suspected flupirtine cases of severe idiosyncratic liver injury. Liver Int 2018;38:365–376.PubMed

106.

Elliott TR, Symes T, Kannourakis G, et al. Resolution of norfloxacin-induced acute liver failure after N-acetylcysteine therapy: further support for the use of NAC in drug-induced ALF? BMJ Case Rep 2016;6:2015-213189.

107.

Zhao Z, Bao L, Yu X, et al. Acute vanishing bile duct syndrome after therapy with cephalosporin, metronidazole, and clotrimazole: a case report. Medicine 2017;96:e8009.PubMedPubMedCentral

108.

Danica J, Irena H, Davor R, et al. Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol 2010;106:62–65.PubMed

109.

Doherty GJ, Duckworth AM, Davies SE, et al. Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury. ESMO Open 2017;2:e000268.PubMedPubMedCentral

110.

Kurokawa K, Hara M, Iwakami S-I, et al. Cholestatic liver injury induced by pembrolizumab in a patient with lung adenocarcinoma. Intern Med 2019;58:3283–3287.PubMedPubMedCentral

111.

Wree A, Dechêne A, Herzer K, et al. Steroid and ursodesoxycholic acid combination therapy in severe drug-induced liver injury. Digestion 2011;84:54–59.PubMed

112.

Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol 2013;169:1071–1080.PubMed

113.

Darnell EP, Mooradian MJ, Baruch EN, et al. Immune-related adverse events (irAEs): diagnosis, management, and clinical pearls. Curr Oncol Rep 2020;22:39.PubMed

114.

Czaja AJ. Drug-induced autoimmune-like hepatitis. Dig Dis Sci 2011;56:958–976.PubMed

115.

Nishida N, Kudo M. Liver damage related to immune checkpoint inhibitors. Hepatol Int 2019;13:248–252.PubMed

116.

Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002;137:947–954.PubMed

117.

Serper M, Wolf MS, Parikh NA, et al. Risk factors, clinical presentation, and outcomes in overdose with acetaminophen alone or with combination products: results from the acute liver failure study group. J Clin Gastroenterol 2016;50:85.PubMedPubMedCentral

118.

Hillman L, Gottfried M, Whitsett M, et al. Clinical features and outcomes of complementary and alternative medicine induced acute liver failure and injury. Am J Gastroenterol 2016;111:958–965.PubMedPubMedCentral

119.

Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a US multicenter, prospective study. Hepatology 2010;52:2065–2076.PubMed

120.

Adam R, Karam V, Cailliez V, et al 2018 annual report of the European Liver Transplant Registry (ELTR)—50-year evolution of liver transplantation. Transpl Int 2018;31:1293–1317.PubMed

121.

Saliba F, Camus C, Durand F, et al. Albumin dialysis with a noncell artificial liver support device in patients with acute liver failure: a randomized, controlled trial. Ann Intern Med 2013;159:522–531.PubMed

122.

Larsen FS, Schmidt LE, Bernsmeier C, et al. High-volume plasma exchange in patients with acute liver failure: an open randomised controlled trial. J Hepatol 2016;64:69–78.PubMed

123.

Chiew AL, Gluud C, Brok J, et al. Interventions for paracetamol (acetaminophen) overdose. Cochrane Database Syst Rev 2018;2:Cd003328.PubMed

124.

Stravitz RT, Sanyal AJ, Reisch J, et al. Effects of N-acetylcysteine on cytokines in non-acetaminophen acute liver failure: potential mechanism of improvement in transplant-free survival. Liver International 2013;33:1324–1331.PubMedPubMedCentral

125.

Singh S, Hynan LS, Lee WM, et al. Improvements in hepatic serological biomarkers are associated with clinical benefit of intravenous N-acetylcysteine in early stage non-acetaminophen acute liver failure. Dig Dis Sci 2013;58:1397–1402.PubMedPubMedCentral

126.

Kortsalioudaki C, Taylor RM, Cheeseman P, et al. Safety and efficacy of N-acetylcysteine in children with non-acetaminophen-induced acute liver failure. Liver Transpl 2008;14:25–30.PubMed

127.

Squires RH, Dhawan A, Alonso E, et al. Intravenous N-acetylcysteine in pediatric patients with nonacetaminophen acute liver failure: a placebo-controlled clinical trial. Hepatology 2013;57:1542–1549.PubMed

128.

Hunt CM, Forster JK, Papay JI, et al. Evidence-based liver chemistry monitoring in drug development. Pharm Med 2009;23:149–158.

129.

Boelsterli UA. Chapter 21—mechanisms underlying the hepatotoxicity of nonsteroidal antiinflammatory drugs. In: Kaplowitz N, DeLeve LD, editors. Drug-induced liver disease. 3rd ed. Boston: Academic Press; 2013. p. 343–367.

130.

Björnsson ES. Drug-induced liver injury: an overview over the most critical compounds. Arch Toxicol 2015;89:327–334.PubMed

131.

Ribas A, Hodi FS, Callahan M, et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013;368:1365–1366.PubMed

132.

Dara L, Liu ZX, Kaplowitz N. Mechanisms of adaptation and progression in idiosyncratic drug induced liver injury, clinical implications. Liver Int 2016;36:158–165.PubMed

133.

Navarro VJ, Khan I, Björnsson E, et al. Liver injury from herbal and dietary supplements. Hepatology 2017;65:363–373.PubMed

134.

Li C, Rao T, Chen X, et al. HLA-B* 35: 01 allele is a potential biomarker for predicting polygonum multiflorum-induced liver injury in humans. Hepatology 2019;70:346–357.PubMed

135.

Zhang L, Niu M, Wei A-W, et al. Risk profiling using metabolomic characteristics for susceptible individuals of drug-induced liver injury caused by Polygonum multiflorum. Arch Toxicol 2020;94:245–256.PubMed

136.

Aiso M, Takikawa H, Tsuji K, et al. Analysis of 307 cases with drug-induced liver injury between 2010 and 2018 in Japan. Hepatol Res 2019;49:105–110.PubMed

137.

Dai N, Yu Y-C, Ren T-H, et al. Gynura root induces hepatic veno-occlusive disease: a case report and review of the literature. World J Gastroenterol WJG 2007;13:1628.PubMed

138.

Helmy A. updates in the pathogenesis and therapy of hepatic sinusoidal obstruction syndrome. Aliment Pharmacol Ther 2006;23:11–25.PubMed

139.

Xiao X, Tang J, Mao Y, et al. Guidance for the clinical evaluation of traditional Chinese medicine-induced liver injuryIssued by China Food and Drug Administration. Acta Pharm Sin B 2019;9:648.PubMed

140.

Yu Y-c, Mao Y-m, Chen C-w, et al. CSH guidelines for the diagnosis and treatment of drug-induced liver injury. Hepatol Int 2017;11:221–241.PubMed

141.

Xia Q, Zhao Y, Lin G, et al. Pyrrolizidine alkaloid-protein adducts: potential non-invasive biomarkers of pyrrolizidine alkaloid-induced liver toxicity and exposure. Chem Res Toxicol 2016;29:1282–1292.PubMed

142.

Wang Y, Wang Z, Gao M, et al. Efficacy and safety of magnesium isoglycyrrhizinate injection in patients with acute drug-induced liver injury: a phase II trial. Liver Int 2019;39:2102–2111.PubMed

143.

Zhu Y, Niu M, Chen J, et al. Hepatobiliary and pancreatic: comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J Gastroenterol Hepatol 2016;31:1476–1482.PubMed

144.

Medina-Caliz I, Garcia-Cortes M, Gonzalez-Jimenez A, et al. Herbal and dietary supplement-induced liver injuries in the Spanish DILI registry. Clin Gastroenterol Hepatol 2018;16:1495–1502.PubMed

145.

Devarbhavi H. Ayurvedic and herbal medicine-induced liver injury: It is time to wake up and take notice. Indian J Gastroenterol 2018;37(1):5–7. https://doi.org/10.1007/s12664-018-0820-6 ((Epub 2018 Feb 8)).CrossRefPubMed

146.

Pandey M, Rastogi S, Rawat A. Indian traditional ayurvedic system of medicine and nutritional supplementation. Evidence-Based Complementary and Alternative Medicine 2013;2013:376327. https://doi.org/10.1155/2013/376327.

147.

Rudra S, Kalra A, Kumar A, et al. Utilization of alternative systems of medicine as health care services in India: evidence on AYUSH care from NSS 2014. PLoS ONE 2017;12:e0176916.PubMedPubMedCentral

148.

Devarbhavi H, Joseph T, Kumar NS, et al. Causes, clinical features, outcomes and predictors of mortality from a nationwide prospective study of drug-induced liver injury. Hepatology 2019;70:1219A.

149.

Devarbhavi H, Choudhury AK, Sharma MK, et al. Drug-induced acute-on-chronic liver failure in Asian patients. Am J Gastroenterol 2019;114:929–937.PubMed

150.

Philips CA, Paramaguru R, Joy AK, et al. Clinical outcomes, histopathologic patterns and chemical analysis of ayurveda and herbal medicine associated with severe liver injury—a single center experience from South India. Indian J Gastroenterol 2018;37:9–17.

151.

Philips CA, Paramaguru R, Augustine P, et al. A Single-center experience on outcomes of complementary and alternative medicine use among patients with cirrhosis. Hepatol Commun 2019;3:1001–1012.PubMedPubMedCentral

152.

Chauhan A, Semwal DK, Mishra SP, et al. Ayurvedic research and methodology: present status and future strategies. Ayu 2015;36:364.PubMedPubMedCentral

153.

Hayashi PH, Barnhart HX, Fontana RJ, et al. Reliability of causality assessment for drug, herbal and dietary supplement hepatotoxicity in the Drug-Induced Liver Injury Network (DILIN). Liver Int 2015;35:1623–1632.PubMed

154.

Danan G, Teschke R. RUCAM in drug and herb induced liver injury: the update. Int J Mol Sci 2016;17:14.

155.

Philips CA, Augustine P, Rajesh S, et al. Complementary and alternative medicine-related drug-induced liver injury in Asia. J Clin Transl Hepatol 2019;7:263.PubMedPubMedCentral

156.

Agarwal VK, McHutchison JG, Hoofnagle JH, et al. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010;8:463–470.PubMedPubMedCentral

157.

Teschke R, Bahre R. Severe hepatotoxicity by Indian ayurvedic herbal products: a structured causality assessment. Ann Hepatol 2009;8:258–266.PubMed

158.

Andrade RJ, Robles-Díaz M. Diagnostic and prognostic assessment of suspected drug-induced liver injury in clinical practice. Liver Int 2020;40:6–17.PubMed

159.

Hayashi PH, Rockey D, Fontana RJ, et al. Death and liver transplantation within two years of onset of drug-induced liver injury. Hepatology 2017;23:29283.

160.

Grewal P, Ahmad J. Severe liver injury due to herbal and dietary supplements and the role of liver transplantation. World J Gastroenterol 2019;25:6704.PubMedPubMedCentral

161.

Andrade RJ. Landscape of liver injury from herbal and dietary supplements in Europe, Latin America, and Asia. Clin Liver Dis 2019;14:49.

162.

Philips CA, Rajesh S, George T, et al. Outcomes and toxicology of herbal drugs in alcoholic hepatitis—a single center experience from India. J Clin Transl Hepatol 2019;7:329.PubMedPubMedCentral

163.

Patwardhan B. Ayurvedic drugs in case: claims, evidence, regulations and ethics. J Ayurveda Integr Med 2016;7:135.PubMedPubMedCentral

164.

Tweed CD, Wills GH, Crook AM, et al. Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB study. BMC Med 2018;16:46.PubMedPubMedCentral

165.

Singanayagam A, Sridhar S, Dhariwal J, et al. A comparison between two strategies for monitoring hepatic function during antituberculous therapy. Am J Respir Crit Care Med 2012;185:653–659.PubMed

166.

Devarbhavi H, Singh R, Patil M, et al. Outcome and determinants of mortality in 269 patients with combination anti-tuberculosis drug-induced liver injury. J Gastroenterol Hepatol 2013;28:161–167.PubMed

167.

Devarbhavi H, Patil M, Reddy VV, et al. Drug-induced acute liver failure in children and adults: results of a single-centre study of 128 patients. Liver Int 2018;38:1322–9.PubMed

168.

Devarbhavi H. Acute liver failure induced by anti-infectious drugs: causes and management. Curr Hepatol Rep 2017;16:276–285.

169.

Treeprasertsuk S, Huntrakul J, Ridtitid W, et al. The predictors of complications in patients with drug-induced liver injury caused by antimicrobial agents. Aliment Pharmacol Ther 2010;31:1200–1207.PubMed

170.

Rathi C, Pipaliya N, Patel R, et al. Drug induced liver injury at a tertiary hospital in india: etiology, clinical features and predictors of mortality. Ann Hepatol 2017;16:442–450.PubMed

171.

Sarda P, Sharma SK, Mohan A, et al. Role of acute viral hepatitis as a confounding factor in antituberculosis treatment induced hepatotoxicity. Indian J Med Res 2009;129:64–67.PubMed

172.

Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis 2016;63:e147–e195.PubMedPubMedCentral

173.

Udomsinprasert W, Chanhom N, Suvichapanich S, et al. Leukocyte telomere length as a diagnostic biomarker for anti-tuberculosis drug-induced liver injury. Sci Rep 2020;10:1–8.

174.

Li Y, Ren Q, Wu D, et al. Combined 5‐hydroxymethylcytosine content of human leucocyte antigen‐B and human leucocyte antigen‐DQB1 as novel biomarker for anti‐tuberculosis drug‐induced liver injury. Basic Clin Pharmacol Toxicol 2020;127:234–240

175.

Nicoletti P, Devarbhavi H, Goel A, et al. Genetic risk factors in drug-induced liver injury due to isoniazid-containing anti-tuberculosis drug regimens. Clin Pharmacol Ther 2020. https://doi.org/10.1002/cpt.2100. Online ahead of print.

176.

Ormerod LP, Skinner C, Wales J. Hepatotoxicity of antituberculosis drugs. Thorax 1996;51:111–113.PubMedPubMedCentral

177.

Thompson NP, Caplin ME, Hamilton MI, et al. Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J 1995;8:1384–1348.PubMed

178.

Rettenbacher MA, Baumgartner S, Eder-Ischia U, et al. Association between antipsychotic-induced elevation of liver enzymes and weight gain: a prospective study. J Clin Psychopharmacol 2006;26:500–503.PubMed

179.

Bessone F, Dirchwolf M, Rodil MA, et al. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease—a physiopathological and clinical integrated view. Aliment Pharmacol Ther 2018;48:892–913.PubMed

180.

Tarantino G, Conca P, Basile V, et al. A prospective study of acute drug-induced liver injury in patients suffering from non-alcoholic fatty liver disease. Hepatol Res 2007;37:410–415.PubMed

181.

Lammert C, Imler T, Teal E, et al. Patients with chronic liver disease suggestive of nonalcoholic fatty liver disease may be at higher risk for drug-induced liver injury. Clin Gastroenterol Hepatol 2019;17:2814–2015.PubMed

182.

Sulkowski MS, Thomas DL, Mehta SH, et al. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections. Hepatology 2002;35:182–189.PubMed

183.

Rutherford A, Davern T, Hay JE, et al. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol 2006;4:1544–1549.PubMed

Titel: Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines
verfasst von: Harshad Devarbhavi
Guruprasad Aithal
Sombat Treeprasertsuk
Hajime Takikawa
Yimin Mao
Saggere M. Shasthry
Saeed Hamid
Soek Siam Tan
Cyriac Abby Philips
Jacob George
Wasim Jafri
Shiv K. Sarin
on behalf of the Asia Pacific Association of Study of Liver
Publikationsdatum: 27.02.2021
Verlag: Springer India
Erschienen in: Hepatology International / Ausgabe 2/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI: https://doi.org/10.1007/s12072-021-10144-3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

23.04.2024 | Ablationstherapie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Drug-induced liver injury: Asia Pacific Association of Study of Liver consensus guidelines

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2021

The main reasons for finite Nuc therapy in HBeAg-negative chronic hepatitis B patients

Correction to: Targeting the ileal bile salt transporter in the treatment of non‑alcoholic fatty liver disease

Does the risk of cardiovascular events differ between biopsy-proven NAFLD and MAFLD?

Dual targeting of PD-L1 and PD-L2 by PCED1B-AS1 via sponging hsa-miR-194-5p induces immunosuppression in hepatocellular carcinoma

Author’s reply to “Thromboelastometry in patients with advanced chronic liver disease: a complex interplay”

Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Wie erfolgreich ist eine Re-Ablation nach Rezidiv?

Europäische Ernährungsgewohnheiten: Das sind die häufigsten Fehler

Neuer Typ-1-Diabetes bei Kindern am Wochenende eher übersehen

Parkinson-Therapie im Wandel – aktuelle Leitlinie im Fokus

Update Innere Medizin